| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/03/2003 | CA2461696A1 Compositions and methods for inhibiting eccrine perspiration in humans |
| 04/03/2003 | CA2461693A1 Dosage form for treatment of diabetes mellitus |
| 04/03/2003 | CA2461684A1 Modified release dosage forms |
| 04/03/2003 | CA2461682A1 Composite dosage forms |
| 04/03/2003 | CA2461663A1 Conjugated anti-psychotic drugs and uses thereof |
| 04/03/2003 | CA2461656A1 Modified release dosage forms |
| 04/03/2003 | CA2461653A1 Edible composition and dosage form comprising an edible shell |
| 04/03/2003 | CA2461630A1 Organoleptically acceptable intraorally disintegrating compositions |
| 04/03/2003 | CA2461616A1 Composite dosage forms having an inlaid portion |
| 04/03/2003 | CA2461603A1 Substituted amines for the treatment of neurological disorders |
| 04/03/2003 | CA2461539A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
| 04/03/2003 | CA2461532A1 Use of isogenic human cancer cells for high-throughput screening and drug discovery |
| 04/03/2003 | CA2461526A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes |
| 04/03/2003 | CA2461477A1 Antisense oligonucleotides and methods to induce tumor cell death |
| 04/03/2003 | CA2461467A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 04/03/2003 | CA2461421A1 Material consisting of at least a biodegradable polymer and cyclodextrins |
| 04/03/2003 | CA2461410A1 Dna providing system |
| 04/03/2003 | CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| 04/03/2003 | CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| 04/03/2003 | CA2461357A1 Method for inhibiting the proliferation of hepatic stellate cells with a ligand of the low affinity glucocorticoid binding site (lags) |
| 04/03/2003 | CA2461345A1 Use of pyy or agonist thereof to modify feeding behaviour |
| 04/03/2003 | CA2461305A1 Methods of suppressing microglial activation and systemic inflammatory responses |
| 04/03/2003 | CA2461219A1 Reduced toxicity cisplatin formulations and methods for using the same |
| 04/03/2003 | CA2461150A1 Amines with antialcoholic agents |
| 04/03/2003 | CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity |
| 04/03/2003 | CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| 04/03/2003 | CA2461136A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 04/03/2003 | CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | CA2461128A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders |
| 04/03/2003 | CA2461095A1 Process for making substituted pyrazoles |
| 04/03/2003 | CA2461091A1 Use of hmgb1 for the activation of dendritic cells |
| 04/03/2003 | CA2461089A1 Pharmaceutically acceptable salts of 20(s)-camptothecins |
| 04/03/2003 | CA2461080A1 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole |
| 04/03/2003 | CA2461044A1 Intraorally disintegrating valdecoxib compositions |
| 04/03/2003 | CA2461042A1 Process for the preparation of fast dissolving dosage form |
| 04/03/2003 | CA2460787A1 Prevention and treatment of restenosis by local administration of drug |
| 04/03/2003 | CA2460777A1 Thrombus/thrombogenesis inhibitors |
| 04/03/2003 | CA2460541A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer |
| 04/03/2003 | CA2460500A1 Topical compositions containing fluid-absorbent solids and adhesive fluids |
| 04/03/2003 | CA2460344A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 04/03/2003 | CA2460000A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 04/03/2003 | CA2459976A1 Opioid formulations having reduced potential for abuse |
| 04/03/2003 | CA2459943A1 Androstanes as androgen receptor modulators |
| 04/03/2003 | CA2459926A1 Screening and selection methods for statin drug combinations |
| 04/03/2003 | CA2459807A1 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| 04/03/2003 | CA2459789A1 3-desoxy-vitamin d3 analog esters |
| 04/03/2003 | CA2459125A1 Substituted phenol compounds useful for anesthesia and sedation |
| 04/03/2003 | CA2458661A1 Methods of increasing endogenous testosterone levels |
| 04/03/2003 | CA2458279A1 Modulation of vitamin storage |
| 04/03/2003 | CA2455989A1 Neuroprotective treatment methods using selective inos inhibitors |
| 04/03/2003 | CA2455910A1 Ophthalmologic treatment methods using selective inos inhibitors |
| 04/03/2003 | CA2447984A1 Dosage forms having an inner core and outer shell with different shapes |
| 04/03/2003 | CA2446904A1 Delivery of drug esters through an inhalation route |
| 04/03/2003 | CA2446760A1 Dosage forms having an inner core and outer shell |
| 04/03/2003 | CA2446759A1 Modified release dosage forms |
| 04/03/2003 | CA2443410A1 Bicyclo[3,1,0]hexane containing oxazolidinone antibiotic and derivatives thereof |
| 04/02/2003 | WO2002028821A2 Propionic acid derivatives with ppar-alpha activating properties |
| 04/02/2003 | EP1298348A1 Bush, group of bush, suspension cross-member, vehicle, method for mounting a bush and method for mounting a group of bushes |
| 04/02/2003 | EP1298223A2 Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene |
| 04/02/2003 | EP1298208A2 Ribozymes targeting a hiv tat sequence |
| 04/02/2003 | EP1298199A2 Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
| 04/02/2003 | EP1298132A1 Hydropyridine derivative acid addition salts |
| 04/02/2003 | EP1298131A1 Quinolonecarboxylic acid derivative |
| 04/02/2003 | EP1298125A1 Substituted benzimidazole compounds and their use for the treatment of cancer |
| 04/02/2003 | EP1298124A1 Method For the Preparation of Citalopram |
| 04/02/2003 | EP1297851A1 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 04/02/2003 | EP1297849A1 Remedial agent for optic nerve disease and the like |
| 04/02/2003 | EP1297848A1 Preventives/remedies for granuloma |
| 04/02/2003 | EP1297843A1 Method of photoreduction of hemoglobin vesicles |
| 04/02/2003 | EP1297841A1 Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs |
| 04/02/2003 | EP1297837A1 Remedies for allergic diseases and process for producing the same |
| 04/02/2003 | EP1297836A1 COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED |
| 04/02/2003 | EP1297835A1 Benzo[b]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 04/02/2003 | EP1297834A1 Inhibitor for enzyme having two divalent metal ions as active centers |
| 04/02/2003 | EP1297833A1 Indole carboxylic acids as thyroid receptor ligands |
| 04/02/2003 | EP1297832A2 Composition and methods for treating psoriasis |
| 04/02/2003 | EP1297831A2 Compositions and methods for epidermal chemexfoliation |
| 04/02/2003 | EP1297829A1 Combinations of active ingredients based on polyhydric alcohols and dialkyl substituted acetic acid esters effective against bacterias, mycosis and viruses |
| 04/02/2003 | EP1297828A1 Oral formulations for localized colonic release and the method of preparation thereof |
| 04/02/2003 | EP1297167A1 Tumour-cell specific gene expression and its use in cancer therapy |
| 04/02/2003 | EP1297166A2 Chimeric promoters for controlling expression in smooth muscle cells |
| 04/02/2003 | EP1297147A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 04/02/2003 | EP1297139A2 G-protein coupled receptor org10 |
| 04/02/2003 | EP1297130A2 G-protein coupled receptors |
| 04/02/2003 | EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 04/02/2003 | EP1297108A2 Cell lines and cell-based assays for identification of androgen receptor modulators |
| 04/02/2003 | EP1297005A2 Immunisation against chlamydia pneumoniae |
| 04/02/2003 | EP1297002A2 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 04/02/2003 | EP1297001A1 Amphipathic linear peptides and compositions containing same |
| 04/02/2003 | EP1296998A2 Hcv variants |
| 04/02/2003 | EP1296997A1 Base analogues |
| 04/02/2003 | EP1296996A1 Purine derivatives |
| 04/02/2003 | EP1296995A2 3'-prodrugs of 2'-deoxy-beta-l-nucleosides |
| 04/02/2003 | EP1296990A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 04/02/2003 | EP1296989A2 Polycyclic xanthones as antibiotics |
| 04/02/2003 | EP1296988A1 Azepino 4,5-b]pyrano 3,2-e]indoles |
| 04/02/2003 | EP1296987A1 Compounds for treating impaired fundic relaxation |
| 04/02/2003 | EP1296986A1 5-aminoalkyl-pyrazolo 4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect |
| 04/02/2003 | EP1296984A1 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer |
| 04/02/2003 | EP1296983A1 Novel process for the preparation of pyrazolopyrimidinones |